SCHEMBL22409045

SCHEMBL22409045

CN(C)S(=O)(=O)c1cc(N)ccc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTO1 P78417 3/20 0.50
MAPT P10636 1/20 0.44
ALDH1A1 P00352 7/20 0.43
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 2/20 0.39
KCNJ6 P48051 2/20 0.36
KCNJ5 P48544 2/20 0.36
KCNJ3 P48549 2/20 0.36
MCL1 Q07820 1/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36
KMT2A Q03164 1/20 0.36
PDE2A O00408 1/20 0.36
PDE5A O76074 1/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
NFKB1 P19838 1/20 0.36
APEX1 P27695 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16364899 0.81 ALDH1A1 (0.55) GSTO1ALDH1A1L3MBTL1LMNAMCL1
SCHEMBL29451752 0.79 ALDH1A1 (0.56) ALDH1A1L3MBTL1LMNAKCNJ6KCNJ5
SCHEMBL7537342 0.79 ALDH1A1 (0.56) ALDH1A1L3MBTL1LMNAKCNJ6KCNJ5
Ethane SCHEMBL22412774 0.79 CA2 (0.48) MAPTALDH1A1L3MBTL1MEN1POLB
SCHEMBL22408916 0.78 GSTO1 (0.36) GSTO1MAPTALDH1A1L3MBTL1LMNA
SCHEMBL11683705 0.78 CA2 (0.52) MAPTALDH1A1L3MBTL1MEN1POLB
SCHEMBL1913490 0.78 CA1 (0.44) MAPTALDH1A1L3MBTL1MCL1MEN1
SCHEMBL8936354 0.78 ALDH1A1 (0.61) GSTO1ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL17774585 0.78 ALDH1A1 (0.43) MAPTALDH1A1L3MBTL1MCL1HTT
SCHEMBL29451283 0.77 ALDH1A1 (0.40) GSTO1MAPTALDH1A1L3MBTL1KCNJ6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360120-A1 RAD51 INHIBITORS CYTEIR THERAPEUTICS, INC. 2024-10-31 US disclosed
EP-3938358-B1 RAD51 INHIBITORS CYTEIR THERAPEUTICS INC (US) 2024-10-02 EP disclosed
CN-114072390-B RAD51 inhibitors 赛泰尔治疗公司 2024-06-11 CN disclosed
US-11932636-B2 RAD51 inhibitors CYTEIR THERAPEUTICS, INC. (US) 2024-03-19 US disclosed
US-20220259198-A1 RAD51 INHIBITORS CYTEIR THERAPEUTICS, INC. 2022-08-18 US disclosed
CN-114072390-A RAD51 inhibitors 赛泰尔治疗公司 2022-02-18 CN disclosed
US-11247988-B2 RAD51 inhibitors CYTEIR THERAPEUTICS, INC. (US) 2022-02-15 US disclosed
US-20200291014-A1 RAD51 INHIBITORS CYTEIR THERAPEUTICS, INC. 2020-09-17 US disclosed
WO-2020186006-A1 RAD51 INHIBITORS CYTEIR THERAPEUTICS, INC. (US) 2020-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11247988-B2 RAD51 inhibitors RAD51, MRE11, RAD54L GSTO1 2370/4885MAPT 857/4885ALDH1A1 4493/4885
US-20220259198-A1 RAD51 INHIBITORS RAD51, MRE11, RAD54L GSTO1 2370/4885MAPT 857/4885ALDH1A1 4493/4885
US-20200291014-A1 RAD51 INHIBITORS RAD51, MRE11, RAD54L GSTO1 2370/4885MAPT 857/4885ALDH1A1 4493/4885
US-20240360120-A1 RAD51 INHIBITORS RAD51, MRE11, RAD54L GSTO1 2370/4885MAPT 857/4885ALDH1A1 4493/4885
US-11932636-B2 RAD51 inhibitors RAD51, MRE11, RAD54L GSTO1 2370/4885MAPT 857/4885ALDH1A1 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.